Although systemic targeted therapies are still largely unaffordable in TNBC patients, immunotherapy has recently been introduced in this scenario due to the higher levels of potential immune biomarkers in its microenvironment, such as higher densities of tumor-infiltrating lymphocytes (TILs) and PD-L1 positivity. The gene discussed is CD274; the disease is neoplasm.